{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:39:59Z","timestamp":1785577199889,"version":"3.56.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Jane Lewis-Seaks Endowment"},{"name":"Ceva Sante Animale"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Veterinary Cardiology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.jvc.2017.03.001","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:30:24Z","timestamp":1496277024000},"page":"218-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease"],"prefix":"10.1016","volume":"19","author":[{"given":"M.K.","family":"Ames","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvc.2017.03.001_bib1","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.jvc.2017.03.001_bib2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/01.CIR.96.2.526","article-title":"Hormonal changes and catabolic\/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia","volume":"96","author":"Anker","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jvc.2017.03.001_bib3","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/oxfordjournals.eurheartj.a059429","article-title":"Neuroendocrine response in acute heart failure and the influence of treatment","volume":"10","author":"Broqvist","year":"1989","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jvc.2017.03.001_bib4","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/0002-9149(82)90243-0","article-title":"Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure","volume":"49","author":"Levine","year":"1982","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jvc.2017.03.001_bib5","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure","volume":"82","author":"Francis","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.jvc.2017.03.001_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0002-9149(02)03119-3","article-title":"Neurohormonal prediction of mortality following admission for decompensated heart failure","volume":"91","author":"Aronson","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jvc.2017.03.001_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/hrt.57.1.17","article-title":"Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics","volume":"57","author":"Bayliss","year":"1987","journal-title":"Br Heart J"},{"key":"10.1016\/j.jvc.2017.03.001_bib8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1939-1676.1995.tb01075.x","article-title":"Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group","volume":"9","year":"1995","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.jvc.2017.03.001_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1760-2734(06)70025-X","article-title":"The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: results of a multi-center, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial","volume":"1","year":"1999","journal-title":"J Vet Cardiol"},{"key":"10.1016\/j.jvc.2017.03.001_bib10","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2460\/javma.1998.213.11.1573","article-title":"Effects of enalapril maleate on survival of dogs with naturally occurring acquired heart failure","volume":"213","author":"Ettinger","year":"1998","journal-title":"J Am Vet Med Assoc"},{"key":"10.1016\/j.jvc.2017.03.001_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1760-2734(06)70053-4","article-title":"Comparison of the effects of imidapril and enalapril in a prospective, multicentric randomized trial in dogs with naturally acquired heart failure","volume":"6","author":"Amberger","year":"2004","journal-title":"J Vet Cardiol"},{"key":"10.1016\/j.jvc.2017.03.001_bib12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MED.0b013e3283391989","article-title":"Aldosterone and inflammation","volume":"17","author":"Gilbert","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.jvc.2017.03.001_bib13","doi-asserted-by":"crossref","first-page":"594","DOI":"10.2174\/157016111796642689","article-title":"Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage","volume":"9","author":"Waanders","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jvc.2017.03.001_bib14","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1172\/JCI117269","article-title":"Mineralocorticoids, hypertension, and cardiac fibrosis","volume":"93","author":"Young","year":"1994","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jvc.2017.03.001_bib15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.HYP.0000201443.63240.a7","article-title":"Effects of aldosterone on the vasculature","volume":"47","author":"Schiffrin","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.jvc.2017.03.001_bib16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.jvc.2017.03.001_bib17","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/S0735-1097(01)01237-2","article-title":"Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE)inhibitor administration in chronic heart failure is associated with ACE DD genotype","volume":"37","author":"Cicoira","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jvc.2017.03.001_bib18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0895-7061(03)00913-0","article-title":"Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy","volume":"16","author":"Sato","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jvc.2017.03.001_bib19","first-page":"13","article-title":"Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy","volume":"29","author":"Sato","year":"2001","journal-title":"J Intern Med"},{"key":"10.1016\/j.jvc.2017.03.001_bib20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1388-9842(99)00046-X","article-title":"Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study","volume":"1","author":"Lee","year":"1999","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jvc.2017.03.001_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/hrt.82.1.57","article-title":"How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?","volume":"82","author":"MacFadyen","year":"1999","journal-title":"Heart"},{"key":"10.1016\/j.jvc.2017.03.001_bib22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0735-1097(01)01714-4","article-title":"Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure","volume":"39","author":"Tang","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jvc.2017.03.001_bib23","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.jvc.2017.03.001_bib24","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1440-1797.2006.00665.x","article-title":"Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy","volume":"11","author":"Horita","year":"2006","journal-title":"Nephrology"},{"key":"10.1016\/j.jvc.2017.03.001_bib25","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jash.2012.07.003","article-title":"Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren\u00a0+\u00a0valsartan) therapy","volume":"6","author":"Bomback","year":"2012","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.jvc.2017.03.001_bib26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11906-000-0027-x","article-title":"Spironolactone in congestive heart failure","volume":"2","author":"Soberman","year":"2000","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.jvc.2017.03.001_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1470320316633897","article-title":"Evaluation of subacute change in RAAS activity (as indicated by urinary aldosterone: creatinine, after pharmacologic provocation) and the response to ACE inhibition","volume":"17","author":"Ames","year":"2016","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.jvc.2017.03.001_bib28","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2460\/ajvr.76.12.1041","article-title":"Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs","volume":"76","author":"Ames","year":"2015","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.jvc.2017.03.001_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jvp.12154","article-title":"Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensin-aldosterone system in normal dogs","volume":"38","author":"Lantis","year":"2014","journal-title":"J Vet Pharmacol Ther"},{"key":"10.1016\/j.jvc.2017.03.001_bib30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/jvp.12216","article-title":"The effect of enalapril on furosemide-activated renin-angiotensin-aldosterone system in healthy dogs","volume":"38","author":"Lantis","year":"2015","journal-title":"J Vet Pharmacol Ther"},{"key":"10.1016\/j.jvc.2017.03.001_bib31","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/j.1939-1676.2009.0392.x","article-title":"Guidelines for the diagnosis and treatment of canine chronic valvular heart disease","volume":"23","author":"Atkins","year":"2009","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.jvc.2017.03.001_bib32","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ki.1993.284","article-title":"Dissociation between the course of the hemodynamic and antiproteinuric effects of angiotensin I converting enzyme inhibition","volume":"44","author":"Gansevoort","year":"1993","journal-title":"Kidney Int"},{"key":"10.1016\/j.jvc.2017.03.001_bib33","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/ki.1994.113","article-title":"Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?","volume":"45","author":"Gansevoort","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.jvc.2017.03.001_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000345243","article-title":"Vascular actions of aldosterone","volume":"50","author":"Briet","year":"2013","journal-title":"J Vasc Res"},{"key":"10.1016\/j.jvc.2017.03.001_bib35","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1440-1681.2010.05352.x","article-title":"Expanding view of aldosterone action, with an emphasis on rapid action","volume":"37","author":"Vinson","year":"2010","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jvc.2017.03.001_bib36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00424-008-0616-0","article-title":"Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?","volume":"458","author":"Gekle","year":"2008","journal-title":"Pflugers Arch Eur J Physiol"},{"key":"10.1016\/j.jvc.2017.03.001_bib37","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvc.2017.03.001_bib38","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvc.2017.03.001_bib39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvc.2017.03.001_bib40","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1939-1676.2009.0467.x","article-title":"Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease","volume":"24","author":"Bernay","year":"2010","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.jvc.2017.03.001_bib41","first-page":"175","article-title":"Renin, aldosterone, and hypertension. The hepatic metabolism of renin and aldosterone. A review with new observations on the hepatic clearance of renin","volume":"27","author":"Schneider","year":"1970","journal-title":"Circ Res"},{"key":"10.1016\/j.jvc.2017.03.001_bib42","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1172\/JCI104624","article-title":"The metabolism of aldosterone in normal subjects and in patients with hepatic cirrhosis","volume":"41","author":"Coppage","year":"1962","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jvc.2017.03.001_bib43","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0022-3565(24)35393-5","article-title":"Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic\/pharmacodynamic modeling approach","volume":"292","author":"Toutain","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jvc.2017.03.001_bib44","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2460\/ajvr.1996.57.11.1645","article-title":"Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation","volume":"57","author":"Haggstrom","year":"1996","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.jvc.2017.03.001_bib45","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1365-2885.2007.00894.x","article-title":"The effect of amlodipine and the combination of amlodipine and enalapril on the renin-angiotensin-aldosterone system in the dog","volume":"30","author":"Atkins","year":"2007","journal-title":"J Vet Pharmacol Ther"},{"key":"10.1016\/j.jvc.2017.03.001_bib46","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.2460\/ajvr.72.12.1646","article-title":"Effects of furosemide and the combination of furosemide and the labeled dosage of pimobendan on the circulating renin-angiotensin-aldosterone system in clinically normal dogs","volume":"72","author":"Lantis","year":"2011","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.jvc.2017.03.001_bib47","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2460\/ajvr.2001.62.1793","article-title":"Additive effects of a sodium chloride restricted diet and furosemide administration in healthy dogs","volume":"62","author":"Lovern","year":"2001","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.jvc.2017.03.001_bib48","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1524-6175.2007.05938.x","article-title":"Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients","volume":"9","author":"Champlain","year":"2007","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.jvc.2017.03.001_bib49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/HYPERTENSIONAHA.114.03311","article-title":"Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites","volume":"64","author":"Deo","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.jvc.2017.03.001_bib50","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurjhf\/hft100","article-title":"Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial","volume":"15","author":"Girerd","year":"2014","journal-title":"Eur J Heart Fail"}],"container-title":["Journal of Veterinary Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1760273417300747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1760273417300747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T22:08:08Z","timestamp":1750284488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1760273417300747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1760273417300747"],"URL":"https:\/\/doi.org\/10.1016\/j.jvc.2017.03.001","relation":{},"ISSN":["1760-2734"],"issn-type":[{"value":"1760-2734","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Veterinary Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvc.2017.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}